CN116236526B - Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof Download PDFInfo
- Publication number
- CN116236526B CN116236526B CN202310073960.XA CN202310073960A CN116236526B CN 116236526 B CN116236526 B CN 116236526B CN 202310073960 A CN202310073960 A CN 202310073960A CN 116236526 B CN116236526 B CN 116236526B
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- polycystic ovary
- ovary syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 91
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 206010036049 Polycystic ovaries Diseases 0.000 title description 4
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 19
- 239000002775 capsule Substances 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 235000006751 Platycodon Nutrition 0.000 claims abstract description 14
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 14
- 229930189914 platycodon Natural products 0.000 claims abstract description 14
- 241000213006 Angelica dahurica Species 0.000 claims abstract description 13
- 241000132012 Atractylodes Species 0.000 claims abstract description 13
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 13
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 13
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 13
- 241000830535 Ligustrum lucidum Species 0.000 claims abstract description 13
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 13
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 13
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 13
- 235000011477 liquorice Nutrition 0.000 claims abstract description 13
- 244000236658 Paeonia lactiflora Species 0.000 claims abstract description 12
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims abstract description 12
- 241001180876 Saposhnikovia Species 0.000 claims abstract description 12
- 241000951473 Schizonepeta Species 0.000 claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 241000245665 Taraxacum Species 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 59
- 230000000694 effects Effects 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 210000003734 kidney Anatomy 0.000 abstract description 10
- 206010020565 Hyperaemia Diseases 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 239000003098 androgen Substances 0.000 description 15
- 210000004072 lung Anatomy 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 9
- 201000010066 hyperandrogenism Diseases 0.000 description 8
- 206010000496 acne Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000002874 Acne Vulgaris Diseases 0.000 description 6
- 239000000583 progesterone congener Substances 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 230000002611 ovarian Effects 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 5
- 229960002256 spironolactone Drugs 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 206010020112 Hirsutism Diseases 0.000 description 4
- 229940030486 androgens Drugs 0.000 description 4
- 230000003821 menstrual periods Effects 0.000 description 4
- 230000027758 ovulation cycle Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 3
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 3
- 229960003843 cyproterone Drugs 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229960002568 ethinylestradiol Drugs 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229940126680 traditional chinese medicines Drugs 0.000 description 3
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 201000005670 Anovulation Diseases 0.000 description 2
- 206010002659 Anovulatory cycle Diseases 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 2
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 2
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 231100000552 anovulation Toxicity 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002124 endocrine Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229930007503 menthone Natural products 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 229940127234 oral contraceptive Drugs 0.000 description 2
- 239000003539 oral contraceptive agent Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 1
- SCHQYDNRAYQJBC-AYAFTLGDSA-N (8r,9s,10s,13r,14s,17r)-17-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-7-ol Chemical compound OC1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 SCHQYDNRAYQJBC-AYAFTLGDSA-N 0.000 description 1
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- CNHZRRBWLMSLDX-WNHLAMKZSA-N 2''O-acetylplatycodin D Chemical compound O([C@H]1[C@@H](O)C[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2C1(CO)CO)O)C(=O)O[C@@H]1OC[C@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@H]([C@@H]([C@@H](O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@](O)(CO)CO2)O)[C@H](O)CO1)O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CNHZRRBWLMSLDX-WNHLAMKZSA-N 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241001480036 Epidermophyton floccosum Species 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002682 Hyperkalemia Diseases 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- JYDNKGUBLIKNAM-UHFFFAOYSA-N Oxyallobutulin Natural products C1CC(=O)C(C)(C)C2CCC3(C)C4(C)CCC5(CO)CCC(C(=C)C)C5C4CCC3C21C JYDNKGUBLIKNAM-UHFFFAOYSA-N 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 241001106477 Paeoniaceae Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- KGGGRGBDMBZXKF-UHFFFAOYSA-N Virganreagenin G Natural products C1C(O)C(O)C(C)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C KGGGRGBDMBZXKF-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 102000001307 androgen receptors Human genes 0.000 description 1
- 108010080146 androgen receptors Proteins 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- FVWJYYTZTCVBKE-ROUWMTJPSA-N betulin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(CO)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C FVWJYYTZTCVBKE-ROUWMTJPSA-N 0.000 description 1
- MVIRREHRVZLANQ-UHFFFAOYSA-N betulin Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5C(CCC5(CO)CCC34C)C(=C)C)C1(C)C MVIRREHRVZLANQ-UHFFFAOYSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000009093 first-line therapy Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000002394 ovarian follicle Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229930195126 picroside Natural products 0.000 description 1
- KEUKDVIGAVVGLF-RUYHYXBRSA-N picroside I Natural products OC[C@]12O[C@H]1[C@@H]3O[C@@H](O[C@@H]4O[C@H](COC(=O)C=Cc5ccccc5)[C@@H](O)[C@H](O)[C@H]4O)C=C[C@@H]3[C@H]2O KEUKDVIGAVVGLF-RUYHYXBRSA-N 0.000 description 1
- AKNILCMFRRDTEY-UHFFFAOYSA-N picroside II Natural products C1=C(O)C(OC)=CC(C(=O)OC2C3C(C(OC=C3)OC3C(C(O)C(O)C(CO)O3)O)C3(CO)OC32)=C1 AKNILCMFRRDTEY-UHFFFAOYSA-N 0.000 description 1
- 229930189407 platycodin Natural products 0.000 description 1
- IVDSKBGNLNNRFN-UHFFFAOYSA-N platycodin A Natural products CC1OC(OC2C(O)C(O)COC2OC(=O)C34CCC(C)(C)CC3C5=CCC6C7(C)CC(O)C(OC8CC(CO)C(O)C(O)C8O)C(CO)(CO)C7CCC6(C)C5(C)CC4O)C(OC(=O)C)C(O)C1OC9OCC(O)C(OC%10OCC(O)(CO)C%10O)C9O IVDSKBGNLNNRFN-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- GHIZCSMTYWOBQA-BZSCQJQFSA-N spinasterol Natural products CC[C@H](C=C[C@@H](C)[C@@H]1CC[C@@]2(C)C3=CC[C@@H]4C[C@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C GHIZCSMTYWOBQA-BZSCQJQFSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicine compositions, and discloses a traditional Chinese medicine composition for treating polycystic ovary syndrome and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 9-10 parts of white peony root, 9-10 parts of bighead atractylodes rhizome, 9-10 parts of Chinese angelica, 7-8 parts of szechuan lovage rhizome, 9-10 parts of glossy privet fruit, 4-5 parts of raw liquorice, 9-10 parts of divaricate saposhnikovia root, 9-10 parts of schizonepeta, 4-5 parts of platycodon root, 7-8 parts of weeping forsythiae capsule, 4-5 parts of fried cape jasmine and 12-13 parts of dandelion. The traditional Chinese medicine composition provided by the invention follows the principle of dialectical treatment, nourishes kidney and blood by using the lung-kidney simultaneous treatment method, clears away lung-heat and has obvious treatment effect on polycystic ovary syndrome, especially the treatment thought of lung-kidney homotone aiming at hyperandrogenic hyperemia of polycystic ovary syndrome is explored, and the new progress of traditional Chinese medicine treatment on polycystic ovary syndrome is obtained.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating polycystic ovary syndrome and a preparation method thereof.
Background
Polycystic ovary syndrome (polycystic ovary syndrome, PCOS) is the most common gynecological endocrine disease of adolescent and women of childhood, and the clinical manifestations of the disease are various, and is a heterogeneous syndrome of systemic neuroendocrine-metabolic network disorders, mainly gonadal axis disorders. Diagnostic criteria include anovulation or anovulation, hyperandrogenism and ultrasound examination of polycystic ovary (PCO). Although PCOS has traditionally been considered a reproductive disorder, there is evidence that the prevalence of obese, insulin-resistant patients increases, while many studies now indicate that the disease causes persistent metabolic abnormalities, with long-term leading to increased prevalence of type 2 diabetes, metabolic syndrome, cardiovascular and cerebrovascular diseases, and endometrial cancer. At present, no radical treatment means exists for the disease, and due to the different ages and treatment requirements of PCOS patients and the high heterogeneity of clinical manifestations, the clinical treatment should take individual symptomatic treatment measures according to patient complaints, treatment requirements and metabolic changes so as to achieve the purposes of relieving clinical symptoms, regulating menstrual rhythm, solving fertility problems, maintaining health and improving life quality.
Recent studies have generally recognized that Hyperandrogenemia (HA) plays an important role in the development of most reproductive and metabolic disorders associated with PCOS. HA is considered to be a major clinical marker of PCOS. It is estimated that over 80% of women with PCOS exhibit signs or symptoms of hyperandrogenism, including hirsutism, acne, or alopecia. Drug treatment strategies to control hyperandrogenism aim to reduce androgen levels and control the effects of androgens at the tissue level. The primary method of first-line therapy is currently oral contraceptive (oral contraceptive, OCPS) therapy. OCP contains both estrogen and progestogen, which effectively inhibits pituitary gland-ovary regulation, thereby reducing ovarian androgen production, while the novel progestogen possesses stronger progestogen and weaker androgenic effects. Spironolactone (SPA) is the most commonly used androgen blocker in the united states and is relatively effective in treating all dermatological symptoms of polycystic ovary syndrome, particularly acne and hirsutism. SPA can compete with dihydrotestosterone for androgen receptor binding, locally block 5αr activity, compete with androgen for SHBG binding, and block the effect of androgens in regulating target gene expression in the fur-bearing glandular unit or hair follicle.
OCP contains both estrogen and progestogen, which effectively inhibits pituitary gland-ovary regulation, thereby reducing ovarian androgen production, while the novel progestogen possesses stronger progestogen and weaker androgenic effects. However, these medications may lead to more venous thrombotic events and severely obese patients are forbidden. OCP treatment is primarily through the ability of OCP to increase SHBG and decrease free T levels, alleviating HA clinical symptoms, including hirsutism and acne. SPA may lead to hyperkalemia and therefore potassium blood should be monitored. At the same time SPA has potential teratogenicity. In addition, physiological doses of dexamethasone or prednisone can also directly reduce the production of adrenal androgens. The Chinese medicine has different ideas and is currently being explored.
Although PCOS-HA disease name is not specially recorded in the history of traditional Chinese medicine, various generations of doctors observe and search for clinical manifestations of PCOS-HA early, and the manifestations of PCOS-HA symptoms such as delayed menstrual period, amenorrhea, infertility and obesity are observed, so that a theoretical basis is provided for the research of the pathogenesis of PCOS-HA in traditional Chinese medicine.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating polycystic ovary syndrome.
The invention also aims to provide a preparation method of the traditional Chinese medicine composition for treating polycystic ovary syndrome.
In order to solve the technical problems, the first aspect of the invention provides a traditional Chinese medicine composition for treating polycystic ovary syndrome, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 9-10 parts of white peony root, 9-10 parts of bighead atractylodes rhizome, 9-10 parts of Chinese angelica, 7-8 parts of szechuan lovage rhizome, 9-10 parts of glossy privet fruit, 4-5 parts of raw liquorice, 9-10 parts of divaricate saposhnikovia root, 9-10 parts of schizonepeta, 4-5 parts of platycodon root, 7-8 parts of weeping forsythiae capsule, 4-5 parts of fried cape jasmine and 12-13 parts of dandelion.
Preferably, the traditional Chinese medicine composition for treating polycystic ovary syndrome provided by the invention is prepared from the following traditional Chinese medicine raw materials in parts by weight: 9 parts of white peony root, 9 parts of bighead atractylodes rhizome, 10 parts of Chinese angelica, 8 parts of szechuan lovage rhizome, 10 parts of glossy privet fruit, 5 parts of raw liquorice, 9 parts of divaricate saposhnikovia root, 9 parts of fineleaf schizonepeta herb, 5 parts of platycodon root, 8 parts of weeping forsythiae capsule, 5 parts of fried cape jasmine fruit and 12 parts of dandelion.
The second aspect of the invention provides a preparation method of a traditional Chinese medicine composition for treating polycystic ovary syndrome, which comprises the following steps: the preparation method comprises the following steps of (1) weighing the following traditional Chinese medicine raw materials in parts by weight: 9-10 parts of white peony root, 9-10 parts of bighead atractylodes rhizome, 9-10 parts of Chinese angelica, 7-8 parts of szechuan lovage rhizome, 9-10 parts of glossy privet fruit, 4-5 parts of raw liquorice, 9-10 parts of divaricate saposhnikovia root, 9-10 parts of schizonepeta, 4-5 parts of platycodon root, 7-8 parts of weeping forsythiae capsule, 4-5 parts of fried cape jasmine and 12-13 parts of dandelion; (2) Mixing the traditional Chinese medicine raw materials, and decocting and extracting with water to obtain the traditional Chinese medicine composition for treating polycystic ovary syndrome.
Preferably, in the step (1), the following traditional Chinese medicine raw materials in parts by weight are weighed: 9 parts of white peony root, 9 parts of bighead atractylodes rhizome, 10 parts of Chinese angelica, 8 parts of szechuan lovage rhizome, 10 parts of glossy privet fruit, 5 parts of raw liquorice, 9 parts of divaricate saposhnikovia root, 9 parts of fineleaf schizonepeta herb, 5 parts of platycodon root, 8 parts of weeping forsythiae capsule, 5 parts of fried cape jasmine fruit and 12 parts of dandelion.
Preferably, 400ml to 800ml of water is added in the water decoction extraction in the step (2), and the water decoction is carried out for 0.5 to 1 hour after 0.5 to 2 hours of soaking.
Optionally, the preparation method of the traditional Chinese medicine composition for treating polycystic ovary syndrome provided by the invention further comprises the step of preparing the traditional Chinese medicine composition for treating polycystic ovary syndrome into a conventional dosage form by a conventional traditional Chinese medicine preparation method.
Optionally, the traditional Chinese medicine composition provided by the invention can be further prepared into granules, tablets, capsules or pills.
The inventors of the present application believe, relative to the prior art, that correction of androgen metabolism disorders is critical in the treatment of PCOS. At present, the strategy for treating PCOS-HA in the traditional Chinese medicine field does not form a unified theory, and the inventor of the application creatively proposes to treat PCOS-HA by using the traditional Chinese medicine composition and places the focus of emasculation treatment of the disease on lung and kidney. The inventor starts from androgen metabolism pathway through holy menstruation regulating formula treatment, carries out clinical observation on PCOS-HA patients for 3 menstrual cycles, evaluates clinical and serum biochemical indexes and the like, particularly evaluates related curative effects of high androgen level, proves the treatment effect of the traditional Chinese medicine composition on PCOS-HA, explores the treatment thought of PCOS-HA lung and kidney coherence, and provides a brand new angle for deeply understanding traditional Chinese medicine treatment PCOS.
Specifically, the inventors believe that lung governs qi of the whole body and blood generation is closely related to lung qi regulation. The excessive accumulation of the lung qi stagnation can not occur, but the ascending and descending of the lung qi stagnation can not occur, so that acne and hair can not occur. The disease of phlegm-dampness is not self-generated, and water cannot be circulated due to stagnation of fire-heat, stagnation is phlegm, exterior is obesity, interior is ovarian nest capsule. The traditional Chinese medicine composition provided by the invention follows the principle of dialectical treatment, and the lung and kidney are treated simultaneously to nourish the kidney and blood, clear lung and cause depression. In particular, in the traditional Chinese medicine composition provided by the invention, the exterior syndrome relieving medicine is firstly applied to treat polycystic ovary syndrome hyperandrogenic syndrome. Herba schizonepetae: sex-pungent and slightly warm; enter lung and liver meridians; is mainly used for relieving exterior syndrome, dispelling wind and promoting eruption; the chemical component contains 1.8% of volatile oil, wherein the main component of the oil is dextro menthone, racemo menthone and a small amount of dextro limonene; the pharmacological action is in vitro, and the high concentration (1:100) has the effect of resisting tubercle bacillus. Wind prevention: pungent and sweet, warm; enter the bladder, liver and spleen meridians; is mainly used for relieving exterior syndrome, dispelling wind, eliminating dampness and relieving spasm; the chemical components comprise volatile oil, mannitol, picroside and the like; the pharmacological effects can relieve fever, relieve pain and resist bacteria. Radix Platycodi: bitter and pungent properties, and flat; enter lung meridian; mainly used for dispersing lung qi, relieving sore throat, eliminating phlegm and expelling pus; the root contains saponin, which is known to contain polygalacic acid, platycodin and glucose, spinasterol, alpha-spinasterol dill-beta-D-glucoside, delta 7-stigmastanol and betulin, inulin and platycodon, and three triterpene substances are obtained from platycodon simultaneously: platycodin A, B and C; the pharmacological effects can eliminate phlegm, reduce blood sugar, influence cholesterol metabolism, and inhibit Epidermophyton floccosum. Radix Saposhnikoviae, herba Schizonepetae, and radix Platycodi are wind-evil herbs, and are effective in dispersing pathogenic wind, slightly floating, and removing upper jiao, and in treating polycystic ovary syndrome hyperandrogenism, can open and dredge striae, and resolve heat stagnation. In addition, the Chinese medicinal composition comprises radix Paeoniae alba, rhizoma Ligustici Chuanxiong, fructus Ligustri Lucidi, etc. which are used as water, and has effects of nourishing yin, invigorating kidney, replenishing blood, dispelling pathogenic wind, nourishing blood, and clearing heat; radix Glycyrrhizae is added to strengthen the spleen and replenish qi to assist in nourishing blood and clearing heat. In summary, the pungent and dispersed drugs are used for relieving the flame, and the effects of dispelling heat and promoting diuresis, nourishing kidney and blood are achieved. Only this one aspect can embody the wonderful method of treating both lung and kidney.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, embodiments of the present invention will be described in detail below. However, those of ordinary skill in the art will understand that in various embodiments of the present invention, numerous technical details have been set forth in order to provide a better understanding of the present application. However, the technical solutions claimed in the present application can be implemented without these technical details and with various changes and modifications based on the following embodiments.
Chinese medicinal composition
According to a first aspect of the present invention, an embodiment of the present invention provides a traditional Chinese medicine composition for treating polycystic ovary syndrome, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 9-10 parts of white peony root, 9-10 parts of bighead atractylodes rhizome, 9-10 parts of Chinese angelica, 7-8 parts of szechuan lovage rhizome, 9-10 parts of glossy privet fruit, 4-5 parts of raw liquorice, 9-10 parts of divaricate saposhnikovia root, 9-10 parts of schizonepeta, 4-5 parts of platycodon root, 7-8 parts of weeping forsythiae capsule, 4-5 parts of fried cape jasmine and 12-13 parts of dandelion.
Preparation of Chinese medicinal composition
According to a second aspect of the present invention, an embodiment of the present invention further provides a method for preparing a Chinese medicinal composition for treating polycystic ovary syndrome, comprising the steps of: the preparation method comprises the following steps of (1) weighing the following traditional Chinese medicine raw materials in parts by weight: 9-10 parts of white peony root, 9-10 parts of bighead atractylodes rhizome, 9-10 parts of Chinese angelica, 7-8 parts of szechuan lovage rhizome, 9-10 parts of glossy privet fruit, 4-5 parts of raw liquorice, 9-10 parts of divaricate saposhnikovia root, 9-10 parts of schizonepeta, 4-5 parts of platycodon root, 7-8 parts of weeping forsythiae capsule, 4-5 parts of fried cape jasmine and 12-13 parts of dandelion; (2) Mixing the traditional Chinese medicine raw materials, and decocting and extracting with water to obtain the traditional Chinese medicine composition for treating polycystic ovary syndrome.
In some embodiments of the present invention, in the water-decocting extraction in the step (2), 400ml to 800ml of water is added, and after soaking for 0.5 to 2 hours, the water-decocting is performed for 0.5 to 1 hour.
In some embodiments of the present invention, the method further comprises preparing the traditional Chinese medicine composition for treating polycystic ovary syndrome into a conventional dosage form by a conventional traditional Chinese medicine preparation method.
In some embodiments of the present invention, the Chinese medicinal composition provided by the present invention may be further prepared into a granule, a tablet, a capsule or a pill.
Advantages of the present application are further described below in connection with the examples of the invention. It should be understood that the examples are illustrative of the present application and are not intended to limit the scope of the present application.
EXAMPLE 1 preparation of the Chinese medicinal composition of the invention Water decoction (Tongsheng Tongjing prescription)
Weighing the following traditional Chinese medicine raw materials in parts by weight: 9 parts of white peony root, 9 parts of bighead atractylodes rhizome, 10 parts of Chinese angelica, 8 parts of szechuan lovage rhizome, 10 parts of glossy privet fruit, 5 parts of raw liquorice, 9 parts of divaricate saposhnikovia root, 9 parts of fineleaf schizonepeta herb, 5 parts of platycodon root, 8 parts of weeping forsythiae capsule, 5 parts of fried cape jasmine fruit and 12 parts of dandelion; mixing the above Chinese medicinal materials, adding 500ml of water, soaking for half an hour, and decocting with water for 30min.
Example 2 clinical trial
1. Clinical data
1.1 case Source
Patients diagnosed with PCOS-HA (kidney deficiency and lung depression) were diagnosed in the institutional dawn hospital gynecology at the university of chinese medicine, shanghai, 1 month to 2022 month 8.
1.2 diagnostic criteria
1.2.1 Western diagnostic criteria
The PCOS-HA diagnostic standard adopts the deer-Tedan standard in 2003, and is specifically as follows:
1) Hyperandrogenic blood disease, the clinical manifestations are mainly hirsutism and acne, and the biochemical manifestations are that: elevated serum Testosterone (T), T > 2.6nmol/L;
2) Ovulation in rare or no;
3) Ultrasonic monitoring met polycystic ovarian signs (ovarian follicles of 2-9 mm diameter on one or both sides. Gtoreq.12, and/or ovarian volume. Gtoreq.10 ml).
Patients according to item 1, plus at least 1 of items 2, 3, are diagnosed with PCOS-HA after excluding other causes that may cause high androgens, such as congenital adrenocortical hyperplasia, cushing's syndrome, androgen-secreting tumors.
1.2.2 diagnostic criteria for TCM
The standards of kidney deficiency and lung depression are as follows, referring to the "Chinese medicine New medicine clinical study guidelines" menoxenia, "Chinese medicine disease diagnosis curative effect standard" female infertility section, "Chinese medicine gynecology" polycystic ovary syndrome section, and "Chinese medicine surgery" acne section:
main symptoms are as follows: (1) after the menstruation delay, the amount is small, or the amenorrhea is caused, (2) the body is obese;
secondary symptoms: (1) long-term infertility, (2) multiple hairs, (9) red pimple or itching pain, (4) thirst and happy drinking, (5) phlegm in the throat, (6) dry stool, scanty and reddish urine, and (7) soreness and weakness of waist;
pulse condition of tongue: (1) red tongue with thin and greasy coating and (3) thin pulse.
Has one of the main symptoms, accords with 3 or more tongue pulse in the secondary symptoms, and can be diagnosed.
1.3 inclusion criteria
1) Women between 18 and 40 years of age;
2) Meanwhile, the patient meets the diagnosis standard of PCOS-HA in Chinese and Western medicine;
3) Patients who signed informed consent.
1.4 exclusion criteria
1) Those who do not meet the inclusion criteria of the project;
2) Patients who have used hormonal drugs in about 3 months;
3) Patients who have used other drugs affecting reproductive or metabolic functions (e.g., anti-obesity drugs, anti-diabetic drugs, and traditional Chinese medicines, etc.) or who have participated in other clinical trials within nearly 3 months;
4) Menoxenia caused by other endocrine factors;
5) Combining other chronic diseases;
6) Similar medicines are adopted in recent times, such as medicines with related or antagonistic actions are taken, so that the curative effect of the medicines is difficult to judge;
7) Study planning, including patients with a history of infectious disease, psychosis, and others, cannot be completed in concert.
2. Research design method
And (3) test design: study was performed using a random grouping method, according to 1:1: the 1 proportion is randomly distributed to a treatment group (the traditional Chinese medicine and western medicine group), a control group I (the western medicine group) and a control group II (the control traditional Chinese medicine and western medicine group). The randomized regimen is exclusively managed by the subject group of individuals who are not involved in the clinical trial.
Sample content: according to the actual situation of the study, a small sample clinical study is to be performed, 30 patients in a treatment group, a control group I and a control group II.
3. Therapeutic method
Treatment group: for 3 treatment courses, each treatment course is 1 month, and the patient starts taking the traditional Chinese medicine composition prepared in example 1 on 3 days of menstrual cycle, namely, the general menstruation regulating prescription and ethinyl estradiol cyproterone tablet (Dain-35), (Schering GmbH & Co. Products KG, national medicine standard J20100003) for 1 time/d, continuously 21 days, stopping taking medicine, and waiting for menstrual period to get damp.
Control group one: for 3 treatment courses, each treatment course is 1 month, and patients in 3 months respectively begin to take ethinyl estradiol cyproterone tablet (Daying-35) (Schering GmbH & Co. Products KG, national medicine standard J20100003) orally on 3 rd day of menstrual cycle for 1 time/d, continuously for 21 days, stopping taking medicine, and waiting for menstrual period to get damp.
Control group two: the preparation method comprises the steps of treating 3 treatment courses, wherein each treatment course is 1 month, patients in 3 months respectively take oral control traditional Chinese medicines (9 parts of white paeony root, 9 parts of bighead atractylodes rhizome, 10 parts of Chinese angelica, 8 parts of szechuan lovage rhizome, 10 parts of glossy privet fruit, 5 parts of raw liquorice, 8 parts of weeping forsythiae capsule, 5 parts of fried capejasmine fruit and 12 parts of dandelion) on 3 rd day of menstrual cycle, adding 500ml of water after mixing the traditional Chinese medicine raw material medicines, and soaking for half an hour, and decocting for 30 minutes) +ethinyl estradiol cyproterone tablet (Dain-35) (Schering GmbH & Co.products KG, national standard J20100003), 1 time/d, continuously stopping taking the medicines for 21 days until menstrual period becomes moist.
4. Observation index
Treatment course and follow-up: three groups of patients had genital endocrine hormone levels before and after treatment (LH, T, DHEA, AMH), respectively. And blood regulation, urine regulation and liver and kidney function before and after treatment were monitored. According to the detection of the safety index, 1 case of the test was withdrawn from the test due to adverse reaction in terms of safety, and no adverse reaction related to the test drug occurred.
5. Results of clinical trials
The results of the clinical trials for the three groups of patients are shown in table 1:
TABLE 1 clinical trial results
5.1 treatment VS control group one
There was no statistical difference in LH (treatment group 11.44±4.46 versus control group 7.95±4.54, p=0.071), T (treatment group 2.90±0.63 versus control group 2.81±0.72, p=0.73), DHEA (treatment group 7.03±2.40 versus control group 9.18±2.81, p=0.056), AMH (treatment group 7.91±4.42 versus control group 8.77±4.15, p=0.63) between the two patients prior to treatment. Post-treatment group T was significantly smaller than control group one (treatment group 1.22±0.34, control group one 1.67±0.48, p=0.013); treatment group DHEA was significantly lower than control group one (treatment group 4.77±1.04, control group one 8.18±1.97, p < 0.001); treatment group LH was slightly lower than control group one (treatment group 6.86±2.33, control group one 7.58±3.27, p=0.533); treatment group AMH was slightly lower than control group one (treatment group 3.60±1.40, control group one 3.77±1.37, p=0.77); no side effects such as liver and kidney function damage are found in all patients.
5.2 treatment VS control group two
There was no statistical difference in LH (treatment 11.44±4.46 vs. control two 11.01±4.09, p=0.753), T (treatment 2.90±0.63 vs. control two 2.84±0.85, p=0.822), DHEA (treatment 7.03±2.40 vs. control two 7.95±1.12, p=0.084), AMH (treatment 7.91±4.42 vs. control two 9.20±3.28, p=0.277) between the two patients prior to treatment. Post-treatment group T was significantly smaller than control group two (treatment group 1.22±0.34, control group two 1.64±0.61, p=0.024); treatment group DHEA was significantly lower than control group two (treatment group 4.77±1.04, control group two 7.58±0.94, p < 0.001); treatment group LH was slightly lower than control group two (treatment group 6.86±2.33, control group two 7.88±3.01, p=0.273); treatment group AMH was slightly lower than control group two (treatment group 3.60±1.40, control group two 3.73±0.41, p= 0.628); no side effects such as liver and kidney function damage are found in all patients.
5.2 conclusion
As can be seen from the comparison of the treatment group and the control group I (western medicine group), the traditional Chinese medicine composition disclosed by the invention can regulate the high androgen state of a PCOS-HA patient, thereby improving the PCOS without obvious toxic or side reaction.
As can be seen from the comparison of the treatment group and the control group II (control traditional Chinese medicine and western medicine group), the traditional Chinese medicine composition disclosed by the invention HAs the effects of further obviously enhancing and regulating the high androgen state of a PCOS-HA patient and improving the PCOS in the traditional Chinese medicine composition Tongsheng Tiaojing prescription and HAs no obvious toxic or side effect.
Claims (7)
1. The traditional Chinese medicine composition for treating polycystic ovary syndrome is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight: 9-10 parts of white peony root, 9-10 parts of bighead atractylodes rhizome, 9-10 parts of Chinese angelica, 7-8 parts of szechuan lovage rhizome, 9-10 parts of glossy privet fruit, 4-5 parts of raw liquorice, 9-10 parts of divaricate saposhnikovia root, 9-10 parts of schizonepeta, 4-5 parts of platycodon root, 7-8 parts of weeping forsythiae capsule, 4-5 parts of fried cape jasmine and 12-13 parts of dandelion.
2. The traditional Chinese medicine composition for treating polycystic ovary syndrome according to claim 1, which is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight: 9 parts of white peony root, 9 parts of bighead atractylodes rhizome, 10 parts of Chinese angelica, 8 parts of szechuan lovage rhizome, 10 parts of glossy privet fruit, 5 parts of raw liquorice, 9 parts of divaricate saposhnikovia root, 9 parts of fineleaf schizonepeta herb, 5 parts of platycodon root, 8 parts of weeping forsythiae capsule, 5 parts of fried cape jasmine fruit and 12 parts of dandelion.
3. The preparation method of the traditional Chinese medicine composition for treating polycystic ovary syndrome is characterized by comprising the following steps:
(1) Weighing the following traditional Chinese medicine raw materials in parts by weight: 9-10 parts of white peony root, 9-10 parts of bighead atractylodes rhizome, 9-10 parts of Chinese angelica, 7-8 parts of szechuan lovage rhizome, 9-10 parts of glossy privet fruit, 4-5 parts of raw liquorice, 9-10 parts of divaricate saposhnikovia root, 9-10 parts of schizonepeta, 4-5 parts of platycodon root, 7-8 parts of weeping forsythiae capsule, 4-5 parts of fried cape jasmine and 12-13 parts of dandelion;
(2) And mixing the traditional Chinese medicine raw materials, and decocting and extracting with water to obtain the traditional Chinese medicine composition for treating polycystic ovary syndrome.
4. The method for preparing a traditional Chinese medicine composition for treating polycystic ovary syndrome according to claim 3, wherein in the step (1), the following traditional Chinese medicine raw materials in parts by weight are weighed: 9 parts of white peony root, 9 parts of bighead atractylodes rhizome, 10 parts of Chinese angelica, 8 parts of szechuan lovage rhizome, 10 parts of glossy privet fruit, 5 parts of raw liquorice, 9 parts of divaricate saposhnikovia root, 9 parts of fineleaf schizonepeta herb, 5 parts of platycodon root, 8 parts of weeping forsythiae capsule, 5 parts of fried cape jasmine fruit and 12 parts of dandelion.
5. The method for preparing a Chinese medicinal composition for treating polycystic ovary syndrome according to claim 3, wherein in the water decoction extraction, water is added for soaking for 0.5-2 hours, and then water decoction is carried out for 0.5-1 hour.
6. The method for preparing the traditional Chinese medicine composition for treating polycystic ovary syndrome according to claim 3, further comprising preparing the traditional Chinese medicine composition for treating polycystic ovary syndrome into a conventional dosage form by a conventional traditional Chinese medicine preparation method.
7. The method for preparing the traditional Chinese medicine composition for treating polycystic ovary syndrome according to claim 6, wherein the traditional Chinese medicine composition for treating polycystic ovary syndrome is prepared into granules, tablets, capsules or pills.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310073960.XA CN116236526B (en) | 2023-02-07 | 2023-02-07 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310073960.XA CN116236526B (en) | 2023-02-07 | 2023-02-07 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116236526A CN116236526A (en) | 2023-06-09 |
| CN116236526B true CN116236526B (en) | 2024-02-06 |
Family
ID=86630668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310073960.XA Active CN116236526B (en) | 2023-02-07 | 2023-02-07 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116236526B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108324913A (en) * | 2018-04-20 | 2018-07-27 | 复旦大学附属金山医院 | A kind of Chinese medicine composition that treating obesity and its application |
-
2023
- 2023-02-07 CN CN202310073960.XA patent/CN116236526B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108324913A (en) * | 2018-04-20 | 2018-07-27 | 复旦大学附属金山医院 | A kind of Chinese medicine composition that treating obesity and its application |
Non-Patent Citations (2)
| Title |
|---|
| 防风通圣散治疗多囊卵巢综合征验案二则;贾美君;浙江中西医结合杂志;27(05);418-420 * |
| 陈英都治疗多囊卵巢综合征经验;陈焱;光明中医;25(10);1782 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116236526A (en) | 2023-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101584797B (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
| CN104162057A (en) | Traditional Chinese medicine composition for treating obese polycystic ovarian syndrome and applications thereof | |
| Shen et al. | The Effects of Traditional Chinese Medicine‐Associated Complementary and Alternative Medicine on Women with Polycystic Ovary Syndrome | |
| CN102120020B (en) | Medicinal composition for treating hyperplastic diseases of breast and hysteromyoma and preparation method thereof | |
| CN106334060B (en) | Pharmaceutical composition for treating obesity type polycystic ovarian syndrome | |
| WO2021253742A1 (en) | Application of wubi chinese yam pills in preparation of drug for treatment of premature ovarian insufficiency | |
| CN106362104A (en) | Pharmaceutical composition for treating polycystic ovary syndrome in adolescence | |
| CN103341092B (en) | Preparation method of powder for treating atrophic vaginitis | |
| CN107213311A (en) | Treat the Chinese medicine composition of early onset hypoovarianism | |
| CN116236526B (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method thereof | |
| Li et al. | Current research on complementary and alternative medicine in the treatment of premature ovarian failure: An update review | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN105943651A (en) | Traditional Chinese medicine composition for treating premature ovarian failure, and application thereof | |
| CN112190645B (en) | Traditional Chinese medicine composition for treating hypomenorrhea caused by thin endometrium and kidney-yang deficiency and application thereof | |
| CN103479859B (en) | Traditional Chinese medicine composition for treating hyperandrogenism of polycystic ovary syndrome | |
| CN113144068A (en) | Traditional Chinese medicine composition for treating kidney deficiency type hypomenorrhea and application thereof | |
| CN106421727A (en) | Traditional Chinese medicine composition for treating painful menstruation and preparation method and application thereof | |
| Zhou et al. | The effect of chinese medicinal herbs in relieving menopausal symptoms in ovariectomized chinese women | |
| CN103330867B (en) | Preparation method of powder for treating senile vaginitis | |
| Yang et al. | Research Progress on the Pharmacological Effects and Clinical Application of Jupi Zhuru Decoction | |
| CN108635457A (en) | A kind of Chinese medicine composition and the preparation method and application thereof for treating constipation | |
| CN101375955B (en) | Sperm-passing formulation for treating non-ejaculation symptom and preparation method thereof | |
| Li et al. | Effect of Wenshentiaojing Decoction on Hormone Level and Follicular Number in Patients with Menstrual Disorder of Polycystic Ovary Syndrome | |
| CN115212265B (en) | Chinese patent medicine for treating polycystic ovary syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |